- Poster presentation
- Open Access
Just a simple observational follow-up study?
© Culliford et al. 2015
- Published: 16 November 2015
- Visual Acuity
- Macular Degeneration
- Observational Cohort Study
Observational cohort studies are usually assumed to be simpler to set up and deliver than a RCT. But what happens when the cohort previously took part in a randomised CTIMP? Its anything but simple. We describe our experience of setting up an observational cohort study of patients who took part in the IVAN trial.
IVAN was a multi-centre RCT comparing bevacizumab with the standard treatment of ranibizumab for the treatment of wet age-related macular degeneration. Participants exited the trial on average 5 years ago, and if they continued to be treated under the NHS would have received ranibizumab. For this follow-up study no treatment is planned, data will be collected on treatment since the end of the trial, most recent visual acuity and imaging of the eye. Visual acuity and imaging data will be collected at a dedicated research visit if participants are willing to attend or from routine sources.
1. MHRA consider this follow-up study falls under the remit of the EU Clinical Trials Directive; i.e. that is a CTIMP, requiring amongst other things SAE reporting.
2. The trial population were elderly; a large proportion is likely to be too infirm to attend or have died. They may also have moved? How do we maximise the number of participants included to make sure the results are meaningful?
3. Some sites had low recruitment so the resources required to initiate and reactivate the site may not make their involvement worthwhile.
We will describe strategies we are using to overcome these challenges.
Acknowledgement and disclaimer
This project is funded by the National Institute for Health Research Health Technology Assessment Programme (project number 07/36/01). The views and opinions expressed therein are those of the authors and do not necessarily reflect those of the HTA, NIHR, NHS or the Department of Health.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.